Nancy Olivieri, MD is widely recognized as one of the preeminent crusaders for research integrity, best interest of patient, academic freedom and as a critic of the ever-expanding corporate influence at universities. She has demonstrated great courage — at great sacrifice — when she acted in accordance with the physician’s…
The Chronicle of Higher Education looks at the increasingly dark side of conflicts of interest in academia.
Two important analyses in Open Medicine , a peer-reviewed, independent, open-access journal, focus on methodological flaws in data analysis of randomized drug trials.
An appalling spectacle is taking place in secret in the U.K. whose stench is reminiscent of the Salem witches trials of 1692!
Dr. Wolpe’s Accusations and Dr. Healy’s Response —–Original Message—– From: Paul Root Wolpe Sent: Tuesday, October 28, 2003 4:30 PM To: VERACARE Subject: Re: Ethics of U Penn surgical “drug implant” experiment Vera, We will have to agree to disagree, so this will be my last email on this. A…
Researcher Who Challenged ADHD industry cleared of misconduct charges Sun, 16 Oct 2005 If you thought that academia could not prey to McCarthyite bullying tactics–or could not possibly fall prey to anything like the Salem witch hunts—think again. Dr. Gretchen LeFever, a clinical psychologist and associate professor in the department…
Medical Confidentiality of Research Subject in Jeopardy–Lawyers Subpoena Anthropologist Sun, 9 Mar 2003 Dr. Sheldon Zink, an anthropologist at the University of Pennsylvania’s Center for Bioethics who was in the operating room when James Quinn had an artificial heart transplant, is fighting a legal battle to preserve a research subject’s…
An investigative report in Mercury News (below) focuses on Stanford University department heads, associate deans and other leaders because “these are senior people who set the tone at the medical school and are role models for junior faculty members.”
Contracts Keep Drug Research Findings Concealed – NY Times Mon, 29 Nov 2004 I. A front page article in the New York Times focuses on academia’s role (culpability) in keeping mum about the unpublished antidepressant clinical trial results. The unnamed focus of the article is the industry-supported American College of…
Debate: Ethics of Surgically Implanting Drug Device in psychiatric patients Wed, 5 Nov 2003 An AHRP Infomail (October 7, 2003) criticizing the ethics of University of Pennsylvania’s planned surgical “drug implant” experiment in psychiatric patients, prompted a debate between AHRP president, Vera Sharav, and bioethicist, Paul Root Wolpe, Ph.D., University…
Bitter Pill for David Healy: academia under pharma influence May 21, 2002 One wonders how many embarrassing causes celebres are needed before academic institutions take back control of the university from the corrosive influence of the pharmaceutical/ biotech industry? In 2000, Dr. David Healy may have been surprised by the…
Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine
The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval.
